BidaskClub upgraded shares of Dynavax Technologies (NASDAQ:DVAX) from a sell rating to a hold rating in a research note issued to investors on Monday morning.
Other analysts have also recently issued reports about the company. Cowen reiterated a buy rating and set a $30.00 price target on shares of Dynavax Technologies in a research report on Friday, November 3rd. Cantor Fitzgerald boosted their price target on Dynavax Technologies from $24.00 to $25.00 and gave the stock an overweight rating in a research report on Thursday, November 9th. Zacks Investment Research cut Dynavax Technologies from a hold rating to a sell rating in a research report on Wednesday, January 10th. Finally, ValuEngine cut Dynavax Technologies from a hold rating to a sell rating in a research report on Friday, December 1st. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. The stock presently has an average rating of Hold and an average target price of $25.17.
Dynavax Technologies (NASDAQ DVAX) opened at $17.00 on Monday. The firm has a market capitalization of $1,075.58, a P/E ratio of -8.72 and a beta of 1.08. Dynavax Technologies has a 52 week low of $3.90 and a 52 week high of $24.45.
In related news, VP David Louis Johnson sold 3,092 shares of the business’s stock in a transaction that occurred on Thursday, January 4th. The stock was sold at an average price of $18.60, for a total transaction of $57,511.20. Following the completion of the sale, the vice president now directly owns 7,780 shares in the company, valued at $144,708. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Robert Coffman sold 7,500 shares of the business’s stock in a transaction that occurred on Wednesday, December 13th. The stock was sold at an average price of $18.90, for a total value of $141,750.00. The disclosure for this sale can be found here. 2.90% of the stock is currently owned by insiders.
A number of large investors have recently modified their holdings of the business. GMT Capital Corp grew its holdings in Dynavax Technologies by 1.7% in the 3rd quarter. GMT Capital Corp now owns 3,057,437 shares of the biopharmaceutical company’s stock valued at $65,735,000 after buying an additional 52,300 shares in the last quarter. Vanguard Group Inc. grew its holdings in Dynavax Technologies by 10.9% in the 2nd quarter. Vanguard Group Inc. now owns 2,024,666 shares of the biopharmaceutical company’s stock valued at $19,538,000 after buying an additional 199,004 shares in the last quarter. State Street Corp grew its holdings in Dynavax Technologies by 19.7% in the 2nd quarter. State Street Corp now owns 839,218 shares of the biopharmaceutical company’s stock valued at $8,099,000 after buying an additional 138,112 shares in the last quarter. C WorldWide Group Holding A S grew its holdings in Dynavax Technologies by 23.3% in the 3rd quarter. C WorldWide Group Holding A S now owns 823,825 shares of the biopharmaceutical company’s stock valued at $17,712,000 after buying an additional 155,610 shares in the last quarter. Finally, Lord Abbett & CO. LLC purchased a new stake in Dynavax Technologies in the 2nd quarter valued at $7,777,000. Institutional investors own 70.54% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This story was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://sportsperspectives.com/2018/02/09/dynavax-technologies-dvax-raised-to-hold-at-bidaskclub.html.
About Dynavax Technologies
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.